A blood test to detect pancreatic cancer early
BLOOD-BASED PROTEOMIC ASSAY FOR PANCREATIC CANCER DETECTION
This study is working on a new blood test to help find pancreatic cancer earlier and more accurately than the current method, which could lead to better treatment options for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10947204 on NIH RePORTER |
What this research studies
This research focuses on developing a blood-based proteomic assay to improve the early detection of pancreatic ductal adenocarcinoma (PDAC), a highly lethal cancer that often shows no symptoms until advanced stages. The study aims to validate a mass spectrometry-based assay that has shown promise in outperforming the current standard biomarker, CA19-9, in detecting PDAC. By conducting thorough analytical and clinical validations, the research seeks to refine the assay's accuracy and establish its effectiveness for clinical use, potentially leading to earlier diagnosis and better treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for pancreatic cancer, such as those with a family history of the disease or specific genetic predispositions.
Not a fit: Patients with advanced pancreatic cancer or those who do not meet the high-risk criteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve early detection of pancreatic cancer, leading to better survival rates for patients.
How similar studies have performed: Previous research has shown success with mass spectrometry-based methods for cancer biomarker detection, indicating a promising approach for this study.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Chen, Ru — Baylor College of Medicine
- Study coordinator: Chen, Ru
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.